Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

Abstract

Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT.

Keywords:

• myopic choroidal neovascularization
• ranibizumab
• anti-vascular endothelial growth factor

Disclosure

Colin S Tan received research support from National Medical Research Council Transition Award and conference support from Bayer and Novartis. SriniVas R Sadda is a Consultant for Allergan, Genentech, Roche, Novartis, Iconic, Thrombogenics, Centervue, Heidelberg, Optos and Carl Zeiss Meditec. SriniVas R Sadda received research support from Allergan, Genentech, Optos, and Carl Zeiss Meditec. The authors report no other conflicts of interest in this work.